WallStreetZenWallStreetZen

NASDAQ: RNTX
Rein Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RNTX

Based on 1 analyst offering 12 month price targets for Rein Therapeutics Inc

Min Forecast
$10.00+719.67%
Avg Forecast
$10.00+719.67%
Max Forecast
$10.00+719.67%

Should I buy or sell RNTX stock?

Based on 1 analyst offering ratings for Rein Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RNTX stock forecasts and price targets.

RNTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-22

1 of 1

Forecast return on equity

Is RNTX forecast to generate an efficient return?

Company
-61.16%
Industry
96.93%
Market
-62.31%
RNTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RNTX forecast to generate an efficient return on assets?

Company
-51.09%
Industry
35.83%
RNTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RNTX earnings per share forecast

What is RNTX's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.97
Avg 2 year Forecast
-$0.81
Avg 3 year Forecast
-$0.97

RNTX revenue forecast

What is RNTX's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$79.6M
Avg 2 year Forecast
$184.0M

RNTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNTX$1.22$10.00+719.67%Buy
CVKD$13.63$32.00+134.78%Buy
NXTC$11.93$25.50+113.75%Strong Buy
LNAI$1.20N/AN/A
NRSN$1.19$14.00+1,076.47%Strong Buy
View Top Biotech Stocks

Rein Therapeutics Stock Forecast FAQ

Is Rein Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: RNTX) stock is to Buy RNTX stock.

Out of 1 analyst, 0 (0%) are recommending RNTX as a Strong Buy, 1 (100%) are recommending RNTX as a Buy, 0 (0%) are recommending RNTX as a Hold, 0 (0%) are recommending RNTX as a Sell, and 0 (0%) are recommending RNTX as a Strong Sell.

If you're new to stock investing, here's how to buy Rein Therapeutics stock.

What is RNTX's earnings growth forecast for 2025-2027?

(NASDAQ: RNTX) Rein Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.01%.

Rein Therapeutics's earnings in 2025 is -$59,151,000.On average, 2 Wall Street analysts forecast RNTX's earnings for 2025 to be -$22,489,429, with the lowest RNTX earnings forecast at -$23,538,159, and the highest RNTX earnings forecast at -$21,440,699. On average, 1 Wall Street analyst forecast RNTX's earnings for 2026 to be -$18,877,137, with the lowest RNTX earnings forecast at -$18,877,137, and the highest RNTX earnings forecast at -$18,877,137.

In 2027, RNTX is forecast to generate -$22,605,955 in earnings, with the lowest earnings forecast at -$22,605,955 and the highest earnings forecast at -$22,605,955.

What is RNTX's revenue growth forecast for 2030-2031?

(NASDAQ: RNTX) Rein Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.

Rein Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast RNTX's revenue for 2030 to be $1,853,921,341, with the lowest RNTX revenue forecast at $349,576,620, and the highest RNTX revenue forecast at $3,358,266,063.

In 2031, RNTX is forecast to generate $4,286,974,617 in revenue, with the lowest revenue forecast at $1,398,306,480 and the highest revenue forecast at $7,175,642,753.

What is RNTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: RNTX) forecast ROA is -51.09%, which is lower than the forecast US Biotechnology industry average of 35.83%.

What is RNTX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RNTX price target, the average RNTX price target is $10.00, with the highest RNTX stock price forecast at $10.00 and the lowest RNTX stock price forecast at $10.00.

The Wall Street analyst predicted that Rein Therapeutics's share price could reach $10.00 by Sep 22, 2026. The average Rein Therapeutics stock price prediction forecasts a potential upside of 719.67% from the current RNTX share price of $1.22.

What is RNTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: RNTX) Rein Therapeutics's current Earnings Per Share (EPS) is -$3.00. On average, analysts forecast that RNTX's EPS will be -$0.97 for 2025, with the lowest EPS forecast at -$1.01, and the highest EPS forecast at -$0.92. On average, analysts forecast that RNTX's EPS will be -$0.81 for 2026, with the lowest EPS forecast at -$0.81, and the highest EPS forecast at -$0.81. In 2027, RNTX's EPS is forecast to hit -$0.97 (min: -$0.97, max: -$0.97).

What is RNTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: RNTX) forecast ROE is -61.16%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.